Harry Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Harry Wu has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- James A. Wells
University of California, San Francisco
1 shared publication - Jennifer A. Doudna
Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA, USA
1 shared publication - Johannes Morstein
Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, CA 91125, USA
1 shared publication Katherine J. Susa
Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, USA
1 shared publication- Keelan Z. Guiley
Department of Cellular and Molecular Pharmacology, Howard Hughes Medical Institute, University of California, San Francisco, CA, USA
1 shared publication - Kevan M. Shokat
Department of Cellular and Molecular Pharmacology, Howard Hughes Medical Institute, University of California, San Francisco, USA
1 shared publication
Latest Publications
- Open Access
Chemical Genetic Targeting of the LRRK2 GTPase Domain
Genetic variants throughout the multi-domain protein leucine-rich repeat kinase 2 ( LRRK2) gene are the most common cause of autosomal dominant Parkinson’s disease, and the most prevalent Parkinson’s-associated LRRK2 variants enhance kinase activity. Hence, the kinase domain has been extensively targeted for therapeutic development. However, clinical progression of LRRK2 kinase inhibitors has been limited by on-target peripheral toxicities linked to strong kinase suppression, raising the question of whether targeting LRRK2 kinase activity through other means could offer a more tunable therapeutic window. LRRK2 is one of two proteins in the human proteome that possess a Roc-COR GTPase domain in tandem with a kinase domain, and the GTPase domain has been shown to intramolecularly regulate kinase output. Here, we ask whether the Roc-COR GTPase can be targeted as an alternative approach to downregulate kinase activity. We utilize a chemical genetic approach to sensitize LRRK2 to existing GTPase inhibitors and show that pharmacologically engaging the Roc-COR GTPase domain in cells decreases but does not fully inhibit LRRK2-mediated Rab10 T73 phosphorylation. This study lays the groundwork for future efforts directed at the development of pharmacological inhibitors for the LRRK2 GTPase, providing an alternative approach for therapies targeting LRRK2-driven Parkinson’s disease.
Open AccessChemical Genetic Targeting of the LRRK2 GTPase Domain
Genetic variants throughout the multi-domain protein leucine-rich repeat kinase 2 ( LRRK2) gene are the most common cause of autosomal dominant Parkinson’s disease, and the most prevalent Parkinson’s-associated LRRK2 variants enhance kinase activity. Hence, the kinase domain has been extensively targeted for therapeutic development. However, clinical progression of LRRK2 kinase inhibitors has been limited by on-target peripheral toxicities linked to strong kinase suppression, raising the question of whether targeting LRRK2 kinase activity through other means could offer a more tunable therapeutic window. LRRK2 is one of two proteins in the human proteome that possess a Roc-COR GTPase domain in tandem with a kinase domain, and the GTPase domain has been shown to intramolecularly regulate kinase output. Here, we ask whether the Roc-COR GTPase can be targeted as an alternative approach to downregulate kinase activity. We utilize a chemical genetic approach to sensitize LRRK2 to existing GTPase inhibitors and show that pharmacologically engaging the Roc-COR GTPase domain in cells decreases but does not fully inhibit LRRK2-mediated Rab10 T73 phosphorylation. This study lays the groundwork for future efforts directed at the development of pharmacological inhibitors for the LRRK2 GTPase, providing an alternative approach for therapies targeting LRRK2-driven Parkinson’s disease.
- Open Access
- 18 November 2025
- Published by Springer Nature in Nature Chemical Biology
- Vol. 22 (2) , 192-204
Temporal photoproximity labeling of ligand-activated EGFR neighborhoods using MultiMap
Photoproximity labeling proteomics (PLP) methods have recently shown that cell surface receptors can form lateral interactome networks. Here, we present a paired set of PLP workflows that dynamically track neighborhood changes for oncogenic epidermal growth factor receptor (EGFR) over time, both outside and inside of cells. We achieved this by augmenting the multiscale PLP workflow we call MultiMap, where three photoprobes with different labeling ranges were photoactivated by one photocatalyst, eosin Y, anchored extracellularly and intracellularly on EGFR. We identified hundreds of neighboring proteins that changed within minutes to over 1 h after the addition of EGF. These neighborhoods reveal dynamic interactomes during early, middle and late signaling that drive phosphorylation, internalization, degradation and transcriptional regulation. This rapid ‘molecular photographic’ labeling approach provides snapshots of signaling neighborhoods, revealing their dynamic nature and potential for drug targeting.
- 18 November 2025
- Published by Springer Nature in Nature Chemical Biology
- Vol. 22 (2) , 192-204
Open AccessTemporal photoproximity labeling of ligand-activated EGFR neighborhoods using MultiMap
Photoproximity labeling proteomics (PLP) methods have recently shown that cell surface receptors can form lateral interactome networks. Here, we present a paired set of PLP workflows that dynamically track neighborhood changes for oncogenic epidermal growth factor receptor (EGFR) over time, both outside and inside of cells. We achieved this by augmenting the multiscale PLP workflow we call MultiMap, where three photoprobes with different labeling ranges were photoactivated by one photocatalyst, eosin Y, anchored extracellularly and intracellularly on EGFR. We identified hundreds of neighboring proteins that changed within minutes to over 1 h after the addition of EGF. These neighborhoods reveal dynamic interactomes during early, middle and late signaling that drive phosphorylation, internalization, degradation and transcriptional regulation. This rapid ‘molecular photographic’ labeling approach provides snapshots of signaling neighborhoods, revealing their dynamic nature and potential for drug targeting.